PROGYNY INC

PROGYNY insider selling keeps pace amid a strong rally—CEO’s July 14 sale shows disciplined liquidity strategy, yet shares stay resilient and growth prospects high.

Progyny CFO’s modest share sales reveal routine portfolio balancing, not a red flag—insider activity remains neutral while the company’s growth outlook stays strong.

Swartz Allison’s disciplined insider selling at Progyny shows a routine portfolio strategy, not a warning of distress, with key shares sold near market lows.

Kevin Gordon’s modest sale of 5,500 Progyny shares at $24.99 shows routine liquidity, not a shift in confidence, amid strong monthly gains and insider buying.

Progyny CFO’s latest 8,275‑share sale shows routine liquidity management, not a signal of distress—investors should weigh insider patterns against the company’s strong fertility‑benefits outlook.

Progyny CFO’s March 4 sale signals cautious insider sentiment; investors should track future trades and earnings to gauge the company’s future direction.

Progyny CFO’s 45,454‑share buy signals long‑term confidence amid near‑flat price, boosting investor sentiment for a rebound in fertility‑benefits growth.

Progyny insider buying signals confidence, undervaluation, and partnership‑driven growth, hinting at a potential rebound for investors.